Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bromopride is a substituted benzamide and dopamine antagonist with prokinetic and antiemetic properties, closely related to metoclopramide but distinguished by a bromine atom in place of chlorine. It acts primarily as a selective antagonist at dopamine D2 receptors in both the central nervous system and gastrointestinal tract, thereby inhibiting dopamine-mediated relaxation of the GI tract, enhancing gastric motility, accelerating gastric emptying, and reducing symptoms such as nausea and vomiting. Its clinical uses include treatment of nausea and vomiting—including postoperative nausea—gastroesophageal reflux disease (GERD), preparation for endoscopy or radiographic studies of the GI tract, hiccups, decreased appetite, flatulence when used in combination products, and management of gastrointestinal adverse effects from radiation therapy. It is generally well tolerated; common side effects include somnolence and fatigue; rare extrapyramidal symptoms may occur[1][2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bromopride.